Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Dr. Mark Socinski covered the TAILOR trial, an Italian study directly comparing second line Taxotere (docetaxel) to Tarceva (erlotinib) in advanced NSCLC patients without an EGFR mutation, in the ASCO Lung Cancer Highlights program. However, as a preview to his comments you'll find in the podcast here, I'll share that he wasn't fond of the trial or the questionable value of the results from it.
Still, the trial is among the ones likely to be most discussed in the field of lung cancer from ASCO 2012, so it's worth hearing what it showed, along with an expert perspective of how to interpret it. Below, you'll find the audio and video versions of the podcast along with the transcript and figures.
Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Audio Podcast
Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Transcript
Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Figs
We'll finish Dr. Socinski's presentation of ASCO Highlights in Lung Cancer with his summary of some work in small cell lung cancer. Look for that soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…